Hyue-Mee Kim1,2, Kyung-Hee Kim2, Jin-Sik Park2, Byung-Hee Oh2. 1. Division of Cardiology, Department of Internal Medicine, Chung-Ang University Hospital, Seoul 06973, Korea. 2. Division of Cardiology, Heart Stroke Vascular Center, Incheon Sejong Hospital, 20, Gyeyangmunhwa-ro, Gyeyang-gu, Incheon 21080, Korea.
Abstract
Background and Objectives: Evidence for effectiveness of early change from angiotensin II receptor blockers (ARBs) or angiotensin-converting enzyme inhibitors (ACEIs) to sacubitril/valsartan is lacking. We aimed to investigate whether early changes to sacubitril/valsartan could improve outcomes in patients with nonischemic dilated cardiomyopathy (DCM) in real-world practice. Materials and Methods: A total of 296 patients with nonischemic DCM who were treated with ARB or ACEI continuously (group A, n = 150) or had their medication switched to sacubitril/valsartan (group S, n = 146) were included. The sacubitril/valsartan group was divided into early change (within 60 days, group S/E, n = 59) and late change (group S/L, n = 87) groups. Changes in echocardiographic parameters from the time of initial diagnosis to the last follow-up were analyzed. Results: Patients in group S showed greater left ventricular (LV) end-diastolic dimension (EDD) (group A vs. S, 61.7 ± 7.4 vs. 66.5 ± 8.0, p < 0.001) and lower LV ejection fraction (LVEF) (28.9 ± 8.2% vs. 23.9 ± 7.5%, p < 0.001) than those in group A at initial diagnosis. During a median follow-up of 76 months, patients in group S/E, ∆ LVEF (%) and ∆ LVESD (mm) were significantly improved compared with those in patients in group A (group A vs. S/E, ∆ LVEF, p = 0.036; ∆ LVESD, p = 0.023) or S/L (group S/E vs. S/L, ∆ LVEF, p = 0.05; ∆ LVESD, p = 0.005). Among patients whose medications were switched to sacubitril/valsartan, those with an earlier change showed a significant correlation with greater LVEF improvement (r = -0.367, p < 0.001) and LV reverse remodeling (r = 0.277, p < 0.001). Conclusions: in patients with nonischemic DCM, an early switch to sacubitril/valsartan was associated with greater improvement in LV function. Patients might benefit in terms of LV function by early switching to sacubitril/valsartan.
RCT Entities:
Background and Objectives: Evidence for effectiveness of early change from angiotensin II receptor blockers (ARBs) or angiotensin-converting enzyme inhibitors (ACEIs) to sacubitril/valsartan is lacking. We aimed to investigate whether early changes to sacubitril/valsartan could improve outcomes in patients with nonischemic dilated cardiomyopathy (DCM) in real-world practice. Materials and Methods: A total of 296 patients with nonischemic DCM who were treated with ARB or ACEI continuously (group A, n = 150) or had their medication switched to sacubitril/valsartan (group S, n = 146) were included. The sacubitril/valsartan group was divided into early change (within 60 days, group S/E, n = 59) and late change (group S/L, n = 87) groups. Changes in echocardiographic parameters from the time of initial diagnosis to the last follow-up were analyzed. Results:Patients in group S showed greater left ventricular (LV) end-diastolic dimension (EDD) (group A vs. S, 61.7 ± 7.4 vs. 66.5 ± 8.0, p < 0.001) and lower LV ejection fraction (LVEF) (28.9 ± 8.2% vs. 23.9 ± 7.5%, p < 0.001) than those in group A at initial diagnosis. During a median follow-up of 76 months, patients in group S/E, ∆ LVEF (%) and ∆ LVESD (mm) were significantly improved compared with those in patients in group A (group A vs. S/E, ∆ LVEF, p = 0.036; ∆ LVESD, p = 0.023) or S/L (group S/E vs. S/L, ∆ LVEF, p = 0.05; ∆ LVESD, p = 0.005). Among patients whose medications were switched to sacubitril/valsartan, those with an earlier change showed a significant correlation with greater LVEF improvement (r = -0.367, p < 0.001) and LV reverse remodeling (r = 0.277, p < 0.001). Conclusions: in patients with nonischemic DCM, an early switch to sacubitril/valsartan was associated with greater improvement in LV function. Patients might benefit in terms of LV function by early switching to sacubitril/valsartan.
Entities:
Keywords:
heart failure; left ventricular remodeling; nonischemic dilated cardiomyopathy; sacubitril/valsartan
Authors: Piotr Ponikowski; Stefan D Anker; Khalid F AlHabib; Martin R Cowie; Thomas L Force; Shengshou Hu; Tiny Jaarsma; Henry Krum; Vishal Rastogi; Luis E Rohde; Umesh C Samal; Hiroaki Shimokawa; Bambang Budi Siswanto; Karen Sliwa; Gerasimos Filippatos Journal: ESC Heart Fail Date: 2014-09
Authors: Melissa A Daubert; Kirkwood Adams; Eric Yow; Huiman X Barnhart; Pamela S Douglas; Susan Rimmer; Casey Norris; Lawton Cooper; Eric Leifer; Patrice Desvigne-Nickens; Kevin Anstrom; Mona Fiuzat; Justin Ezekowitz; Daniel B Mark; Christopher M O'Connor; James Januzzi; G Michael Felker Journal: JACC Heart Fail Date: 2019-01-02 Impact factor: 12.035
Authors: Adam D DeVore; Eugene Braunwald; David A Morrow; Carol I Duffy; Andrew P Ambrosy; Hrishikesh Chakraborty; Kevin McCague; Ricardo Rocha; Eric J Velazquez Journal: JAMA Cardiol Date: 2020-02-01 Impact factor: 14.676
Authors: James L Januzzi; Margaret F Prescott; Javed Butler; G Michael Felker; Alan S Maisel; Kevin McCague; Alexander Camacho; Ileana L Piña; Ricardo A Rocha; Amil M Shah; Kristin M Williamson; Scott D Solomon Journal: JAMA Date: 2019-09-17 Impact factor: 56.272
Authors: Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer Journal: Eur Heart J Date: 2016-05-20 Impact factor: 29.983
Authors: Giuseppe Romano; Giuseppe Vitale; Laura Ajello; Valentina Agnese; Diego Bellavia; Giuseppa Caccamo; Egle Corrado; Gabriele Di Gesaro; Calogero Falletta; Eluisa La Franca; Chiara Minà; Salvatore Antonio Storniolo; Filippo Maria Sarullo; Francesco Clemenza Journal: J Clin Med Date: 2019-12-06 Impact factor: 4.241